Yun‐Xin Lu

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Huai‐Qiang Ju · 3 shared papers, 2016–2025 · strength 0.35
   • Paper Corrigendum to "Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic can… DOI 10.1016/j.canlet.2025.217562↗
   • Paper Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. DOI 10.1016/j.canlet.2016.05.024↗
   • Paper Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activati… DOI 10.1111/jpi.12285↗
2. Paul J. Chiao · 3 shared papers, 2016–2025 · strength 0.35
   • Paper Corrigendum to "Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic can… DOI 10.1016/j.canlet.2025.217562↗
   • Paper Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. DOI 10.1016/j.canlet.2016.05.024↗
   • Paper Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activati… DOI 10.1111/jpi.12285↗
3. Rui‐Hua Xu · 3 shared papers, 2016–2025 · strength 0.35
   • Paper Corrigendum to "Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic can… DOI 10.1016/j.canlet.2025.217562↗
   • Paper Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. DOI 10.1016/j.canlet.2016.05.024↗
   • Paper Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activati… DOI 10.1111/jpi.12285↗
4. You-Ming Tang · 2 shared papers, 2020 · strength 0.25
   • Paper A comprehensive assessment of single nucleotide polymorphisms associated with pancreatic cancer risk: A protocol for sy… DOI 10.1097/md.0000000000020345↗
   • Paper A systematic review and network meta-analysis of single nucleotide polymorphisms associated with pancreatic cancer risk. DOI 10.18632/aging.104128↗
5. Zhuomiao Ye · 2 shared papers, 2020 · strength 0.25
   • Paper A comprehensive assessment of single nucleotide polymorphisms associated with pancreatic cancer risk: A protocol for sy… DOI 10.1097/md.0000000000020345↗
   • Paper A systematic review and network meta-analysis of single nucleotide polymorphisms associated with pancreatic cancer risk. DOI 10.18632/aging.104128↗
6. Dongsheng Zhang · 1 shared paper, 2025 · strength 0.20
   • Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0↗
7. Feng Wang · 1 shared paper, 2025 · strength 0.20
   • Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0↗
8. Feng‐Hua Wang · 1 shared paper, 2025 · strength 0.20
   • Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0↗
9. Ming-Ming He · 1 shared paper, 2025 · strength 0.20
   • Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0↗
10. Wuguo Deng · 1 shared paper, 2016 · strength 0.05
    • Paper Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activati… DOI 10.1111/jpi.12285↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.